BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/
/PRNewswire/ Byondis B.V., an independent, clinical stage Dutch biopharmaceutical company creating precision medicines, today announced that the first.